尽管利来公司的股价, 并且FDA批准了新的减肥药. Lilly stock fell despite strong earnings and FDA approval of new weight drug.

礼来公司股价下跌3.9%，因一位主要投资者抛售股票，尽管公司第四季度盈利强劲，超出预期。 Eli Lilly shares dropped 3.9% after a major investor sold stock, though the company reported strong Q4 earnings exceeding estimates. 美国食品和药物管理局最近批准了其新的口服减肥药Foundayo, The FDA recently approved its new oral weight management drug, Foundayo, boosting analyst sentiment and prompting upgrades. 尽管市场上市幅度巨大,目标看, 但投资者面临竞争和关税带来的风险. Despite a massive market cap and bullish targets, investors face risks from competition and tariffs.